Drug intelligence / Profile preview

Membrex Allogeneic (HER2)

Development stage: Preclinical
Lead developer: Metaclipse Therapeutics
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Membrex Allogeneic (HER2) is a preclinical-stage allogeneic membrane-vesicle based immunotherapy developed by Metaclipse Biopharma for the treatment of HER2-positive breast cancer. The therapeutic platform utilizes membrane vesicles derived from cells, which are then modified with biological adjuvants to stimulate an immune response against tumors expressing the Human Epidermal Growth Factor Receptor 2 (HER2). This approach aims to provide a targeted, off-the-shelf cell-based therapy that enhances the patient's immune system's ability to recognize and eliminate HER2-positive cancer cells.

Brand names: Membrex
Other names: Membrex (Allogeneic HER2)Membrex Allogeneic

Beyond the preview

Go deeper on Membrex Allogeneic (HER2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Membrex Allogeneic (HER2).

Explore the full profile